Treatment Modification to Reduce Symptom Burden in Hemodialysis

T

The Rogosin Institute

Status

Completed

Conditions

End Stage Renal Disease

Treatments

Other: Treatment modification

Study type

Interventional

Funder types

Other

Identifiers

NCT01775800
1207012494

Details and patient eligibility

About

Many patients on hemodialysis experience high rates of symptom burden, such as pain, depression, anxiety and difficulty breathing. This study seeks to reduce these symptoms by modifying the usual guidelines used to manage patients on hemodialysis. For example, rather than trying to keep serum phosphorus below 5.5, patients enrolled in this study may have treatment goals of less than 6.5, in order to reduce the number of pills they need to take and potentially reduce harmful side effects. Blood pressure and serum parathyroid hormone goals will also be modified, to see if these modifications help hemodialysis patients feel better.

Enrollment

16 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • hemodialysis patient
  • transplant ineligible

Exclusion criteria

  • dementia
  • unable to answer questionnaires for any reason

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

16 participants in 2 patient groups

Treatment modification
Experimental group
Description:
Patients in this arm will be treated to different targets of blood pressure, parathyroid hormone and serum phosphorus.
Treatment:
Other: Treatment modification
Usual care
No Intervention group
Description:
Patients will receive the usual hemodialysis care with no modifications

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems